Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 9:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 215 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Control Form 5 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.

NCT00765115
View directory record Official record
Conditions
Alzheimer Disease
Interventions
LY450139, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 50 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 2, 2008 · Synced Oct 30, 2026, 9:58 AM EDT
Not listed Phase 2 Interventional

Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome

NCT05875948
View directory record Official record
Conditions
Hepatorenal Syndrome, Acute Kidney Injury
Interventions
R2R01, Terlipressin
Drug
Lead sponsor
River 2 Renal Corp.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 3 Interventional Results available

Study of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects

NCT00293033
View directory record Official record
Conditions
Pain, Cancer
Interventions
BEMA™, Placebo
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 30, 2026, 9:58 AM EDT
Recruiting Phase 2Phase 3 Interventional

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

NCT05714085
View directory record Official record
Conditions
Heart Failure, Left Ventricular Systolic Dysfunction
Interventions
Vericiguat tablet, Vericiguat suspension, Placebo tablet, Placebo suspension
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
29 Days to 17 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
20
States / cities
Los Angeles, California • Palo Alto, California • San Bernardino, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim2)

NCT02127125
View directory record Official record
Conditions
Insulin Sensitivity
Interventions
Maltodextrin, Synbiotic, Sevelamer
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Oct 30, 2026, 9:58 AM EDT
Suspended Not applicable Interventional

Insulin Sensitivity in Men With the Metabolic Syndrome

NCT00433173
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
intravenous glucose tolerance test, testosterone, anastrozole, goserelin acetate implant, aerobic capacity (VO2 Max), MRI, muscle biopsy, measurement of resting metabolic rate (energy expenditure), Dual energy x-ray absorptiometry, Fasting oral glucose tolerance test
Procedure · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
50 Years to 75 Years · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 3 Interventional Results available

To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel

NCT02005666
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel, DUAC® Gel, Placebo
Drug
Lead sponsor
Zydus Lifesciences Limited
Industry
Eligibility
12 Years to 40 Years
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
12
States / cities
Dinuba, California • Santa Ana, California • Boynton Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 30, 2026, 9:58 AM EDT
Terminated Phase 3 Interventional Results available

A Study of PRN1008 in Patients With Pemphigus

NCT03762265
View directory record Official record
Conditions
Pemphigus
Interventions
Rilzabrutinib, Placebo
Drug
Lead sponsor
Principia Biopharma, a Sanofi Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Boca Raton, Florida • Coral Gables, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 30, 2026, 9:58 AM EDT
Recruiting Phase 1 Interventional

Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers

NCT06136195
View directory record Official record
Conditions
Alcohol Consumption, Heavy Drinker, Alcohol Use Disorder (AUD)
Interventions
Mavoglurant
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects

NCT01129375
View directory record Official record
Conditions
Healthy
Interventions
clopidogrel, placebo, omeprazole
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2011 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Creatine Monohydrate Supplementation and Vascular Endothelial Health

NCT05014659
View directory record Official record
Conditions
Endothelial Dysfunction, Oxidative Stress
Interventions
Creatine monohydrate, Placebo
Dietary Supplement
Lead sponsor
Florida State University
Other
Eligibility
50 Years to 64 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Oct 30, 2026, 9:58 AM EDT
Not listed Phase 3 Interventional

A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon

NCT00577304
View directory record Official record
Conditions
Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Other Autoimmune Disease
Interventions
Nitroglycerin, Topical AmphiMatrix
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
15 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Stanford, California • Denver, Colorado • Farmington, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2010 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease

NCT02697734
View directory record Official record
Conditions
Cushing's Disease
Interventions
osilodrostat, osilodrostat Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
6
States / cities
Aurora, Colorado • Ann Arbor, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Not applicable Interventional

Effect of Supplement on Appetite and GLP-1

NCT06790771
View directory record Official record
Conditions
Hunger
Interventions
High Dose Supplement, Low Dose Supplement, Placebo
Dietary Supplement
Lead sponsor
Texas Christian University
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 4 Interventional Results available

The Health Influences of Puberty (HIP) Study

NCT01775813
View directory record Official record
Conditions
Obesity, Insulin Resistance, Gonadal Dysfunction, Type 2 Diabetes
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
9 Years to 17 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Oct 30, 2026, 9:58 AM EDT
Withdrawn Phase 2 Interventional

Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

NCT04329221
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma, Actinic Keratoses, Skin Cancer, Organ Transplant Recipients, Immunotherapy
Interventions
Calcipotriol Only Product in Cutaneous Dose Form, Vaseline, Topical 5FU
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of KPG-818 in Healthy Subjects

NCT03949426
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
KPG-818
Drug
Lead sponsor
Kangpu Biopharmaceuticals, Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Biology of Resilience

NCT01011465
View directory record Official record
Conditions
Oxytocin, Placebo
Interventions
intranasal oxytocin, Placebo, Social support, No Social Support
Drug · Behavioral
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
22 Years to 65 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 26, 2012 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 2 Interventional

Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis

NCT00676832
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Placebo, COLAL-PRED
Drug
Lead sponsor
Prometheus Laboratories
Industry
Eligibility
18 Years to 75 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
89
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 78 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2010 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of the Combination of Nitrate and Caffeine on Critical Power In Trained Male Cyclists

NCT07501806
View directory record Official record
Conditions
Exercise Performance of Fit Athletes, Exercise Performance, Cycling Performance
Interventions
Dietary Nitrate, Caffeine, Placebo
Dietary Supplement · Other
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Radicle Clarity 24: A Study of Health and Wellness Products on Cognitive Function and Related Health Outcomes

NCT06294431
View directory record Official record
Conditions
Cognitive Function
Interventions
Placebo Control Form 1, Clarity Active Study Product 1.1 Usage, Placebo Control Form 2, Clarity Active Study Product 2.1 Usage, Placebo Control Form 3, Clarity Active Study Product 3.1 Usage, Clarity Active Study Product 3.2 Usage, Placebo Control Form 4, Clarity Active Study Product 4.1 Usage, Placebo Control Form 5, Clarity Active Study Product 5.1 Usage, Clarity Active Study Product 5.2 Usage, Placebo Control Form 6, Clarity Active Study Product 6.1 Usage, Placebo Control 6.1.0, Clarity Active Study Product 6.1.1 Usage, Clarity Active Study Product 6.1.2 Usage
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 105 Years
Enrollment
4,794 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 2 Interventional

Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

NCT02057172
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
HM11260C, liraglutide, Placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 74 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
CA, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Oct 30, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Results available

Chronic Low Back Pain Research Project

NCT00108550
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
gabapentin, Inert placebo
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
21 Years to 70 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 30, 2026, 9:58 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial

NCT07742553
View directory record Official record
Conditions
Spinal Cord Injury, Spinal Cord Injuries, Injuries, Spinal Cord, Spinal Cord Contusion, Spinal Cord Trauma, Trauma, Nervous System, Wounds and Injuries, Spinal Cord Compression, Nervous System Diseases, Spinal Cord Diseases, Gonadal Disorders, Endocrine System Diseases, Hypogonadism, Genital Diseases, Male
Interventions
testosterone cypionate, finasteride, placebo injection, placebo pill
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
4
States / cities
Aurora, Colorado • Gainesville, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 30, 2026, 9:58 AM EDT